Recombinant Human Endostatin Market : Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2028

 

The majority of the body's Basement Membranes (BMs), including vascular basement membranes, contain the protein endostatin. Recombinant human endostatin has been shown to significantly improve patient survival when used to treat late-stage Non-Small-Cell Lung Carcinoma in a number of clinical studies (NSCLC). As a result, the State Food and Drug Administration of China (CFDA) approved recombinant human endostatin (Endostar) for the treatment of NSCLC in September 2005. The liver, lung, and kidney are the organs with the highest levels of endostatin expression.

The Recombinant Human Endostatin Market inhibitor with the most research is endostatin, a polypeptide with 184 amino acids that correspond to the globular domain found at the C-terminal of type XVIII collagen.

Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF/FGF-2) are two growth factors that have the potential to interfere with the pro-angiogenic action of endostatin, an angiogenesis inhibitor. It is a widely studied angiogenesis receptor that also inhibits angiogenesis and causes the death of microvascular endothelial cells. The liver, kidneys, and lungs all express endostatin at high levels.

The C-terminal end of type XVIII collagen is a proteolytic fragment of recombinant human endostatin. It might inhibit cytokines that promote inflammation, thereby reducing hepatic metastasis.

The Recombinant Human Endostatin Market, an increase in the number of research and development projects to identify potential uses for recombinant human endostatin, and ongoing studies to assess the potential of collagen, which promises a breakthrough in the treatment of cancer are the main factors driving the global market for recombinant human endostatin.

Medical applications and scientific applications are the two categories of applications that make up the global market for recombinant human endostatin.

The need for new cancer treatments and rising awareness of the use of the Recombinant Human Endostatin Market among medical professionals, such as doctors and oncologists, are expected to cause the medical application segment to dominate the global recombinant human endostatin market during the forecast period.

Key Players

Pfizer Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., PeproTech, Inc., Onyx Pharmaceuticals, Inc., Genexine, Inc., Hetero., Intas Pharmaceuticals Ltd., and Novartis AG are some of the major companies active in this market.